Enjoy complimentary customisation on priority with our Enterprise License!
The global proteasome inhibitors market size is estimated to grow by USD 2.91 billion at a CAGR of 7.48% between 2023 and 2028.
Proteasome inhibition is a promising therapeutic approach for treating multiple myeloma. Cancer cells have higher levels of proteasome activity compared to normal cells, making them more sensitive to the proapoptotic effects of proteasome inhibition. Therefore, the proteasome is considered a therapeutic target in multiple myeloma. In addition, the limitations of existing therapies are driving the adoption rate of proteasome inhibitors. However, the recent approvals are showing impressive sales growth, which represents the continued strong adoption of proteasome inhibitors for the treatment of multiple myeloma. For instance, NINLARO from Takeda Pharmaceutical Co. Ltd. and KYPROLIS from Amgen Inc. registered an annual sales growth of around 18% and 7%, respectively, in 2021. Along with offsetting the impact of generic erosion on VELCADE, such strong sales growth also continues to drive growth for the market during the forecast period.
Technavio has segmented the market into Route Of Administration, Product, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.
To learn more about this report, Download Report Sample
The market share growth by the oral segment will be significant during the forecast period. The oral segment of the global proteasome inhibitors market refers to the category of drugs that can be taken orally, usually in the form of tablets or capsules. These drugs are specifically designed to inhibit the activity of proteasomes, which are responsible for breaking down proteins in cells.
Get a glance at the market contribution of various segments Download PDF Sample
The oral segment was the largest and was valued at USD 4.00 billion in 2018. By inhibiting proteasomes, these drugs can interfere with the growth and survival of cancer cells, making them an important treatment option for various types of cancers. In recent years, the oral segment in the global proteasome inhibitors market has witnessed significant growth. This can be attributed to several factors. Firstly, the convenience and ease of administration of oral drugs make them more favored among patients when compared to intravenous or injectable alternatives. Further, ongoing advancements in research and development have led to the development of highly potent and selective oral proteasome inhibitors. These new drugs offer improved efficacy, reduced side effects, and better patient tolerance, thereby driving their adoption in clinical practice. Thus, the increased benefits of oral proteasome inhibitors will drive the growth of the oral segment of the global proteasome inhibitors market during the forecast period.
VELCADE is an intravenously administered first-generation proteasome inhibitor, which is a type of targeted therapy developed by Takeda Pharmaceutical Co. Ltd. (Takeda) and Johnson and Johnson. This drug inhibits the proteasome enzyme complex within the cell, which is a part of the cellular machinery. The drug also plays a major role in the regulation of cell division and cell survival. Inhibition of the proteasome enzyme complex leads to apoptosis of the disease-causing cell. VELCADE is the first proteasome inhibitor to receive marketing approval in major regions. Despite the companies receiving an extension on the patent rights of the drug until the end of 2022, the sales of VELCADE have witnessed a significant decline. Also, the heavy side effects associated with the treatment further act as a barrier to the growth of the segment. As a result, the segment is expected to lose a significant share and is expected to be the slowest-growing segment of the proteasome inhibitors market during the forecast period.
KYPROLIS is a carfilzomib (a modified form of tetrapeptide epoxyketone)-based drug. It is a second-generation proteasome inhibitor, which is administered intravenously. It works by inhibiting the tetrapeptide epoxyketone proteasome by binding to the N-terminal threonine-containing active sites of the 20S proteasome. However, to reduce the cost burden on the patients, Amgen Inc. (Amgen) launched a patient assistance program called the Amgen Assist 360 in May 2021, which offers cost benefits such as co-pays and reimbursements. These reimbursement programs are expected to attract and encourage patients with multiple myeloma to undergo treatment using KYPROLIS. Owing to these factors, KYPROLIS is expected to witness high growth globally during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America is expected to benefit significantly from the heavy sales of approved proteasome inhibitors in the region for the treatment of various indications. Currently, three branded proteasome inhibitors and one generic proteasome inhibitor are approved in the region. The patent expiry of the blockbuster drug VELCADE has resulted in the development of generic versions of the drug by various large and mid-sized pharmaceutical vendors in the region. Currently, five vendors in the market are developing the generic version of VELCADE, with large vendors already operating in the market, while Allergan generic is being registered for the treatment of multiple myeloma.
However, despite the decrease in the number of new cases of non-Hodgkin lymphoma, the overall prevalence of the indication in the region is still very high. For instance, non-Hodgkin lymphoma is currently the seventh most prevalent cancer type in the US and is also the sixth most fatal type of cancer in the country. This is resulting in a huge unmet need in the region for advanced therapeutics for the treatment. The market is expected to benefit significantly from the increasing advances in the research of proteasome inhibitors in the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Amgen Inc. - The company offer KYPROLIS proteasome inhibitor based on phase 3 ASPIRE trail to help patients reduce the risk of death over lenalidomide and dexamethasone.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
The huge unmet need for certain cancer therapeutics is notably driving the market growth. Currently, there are only a limited number of approved therapies for multiple myeloma, with three branded proteasome inhibitors and one generic proteasome inhibitor approved. This is primarily because pharmaceutical vendors are more focused on developing therapeutics for more common types of blood cancers, such as leukemia and lymphomas. Also, the complex pathogenesis of myeloma makes it difficult to develop therapeutics for the treatment. Although multiple myeloma is a less common type of blood cancer, the overall prevalence of the indication is still high. For instance, the market also has a very limited number of therapies approved for the treatment of pancreatic cancer.
Moreover, the market witnesses the presence of various vendors developing proteasome inhibitors in the late stages of clinical trials for multiple myeloma and two drugs for pancreatic cancer. The unmet need is expected to attract various large and mid-sized pharmaceutical vendors to conduct studies and launch the product, which is expected to help the market grow significantly during the forecast period.
High market growth potential in developing economies is an emerging trend shaping market growth. The rising demand for advanced therapeutic procedures for treating people diagnosed with cancer, the growing number of research institutes and speciality cancer hospitals, and rising healthcare spending are the major factors encouraging global as well as regional vendors to expand their footprint to developing countries, such as China and India. The healthcare industry, which includes hospitals, clinics, research institutes, and speciality cancer treatment centers, is growing at a significant pace in these economies due to the rise in healthcare expenditure.
Additionally, the increase in the number of large- and mid-sized public and private hospitals providing cancer treatment in developing economies is also augmenting the demand for several advanced therapeutic procedures for treating multiple myeloma cancer patients and proteasome inhibitors for treatment. Hence, the increasing number of end-users providing multiple myeloma cancer treatment is expected to propel the growth of the global proteasome inhibitors market during the forecast period.
The slow regulatory approval process for proteasome inhibitors is a significant challenge hindering market growth. While the market has only three approved drugs, it has already witnessed the patent expiry of the major drug, VELCADE. This has resulted in the launch of a generic version of the drug, and various generics are being developed in the late stages of clinical trials. For instance, Fresenius Kabi AG (a subsidiary of Fresenius SE and Co. KGaA) developed MYLOSOME, a generic version of bortezomib, for the treatment of mantle cell lymphoma and multiple myeloma.
Moreover, the pharmaceutical industry is adopting new technologies to reduce the cost of production to provide cheaper therapeutics like generics to needy people in low- and middle-income countries. As a result, the regulatory bodies are approving the generics over the branded drugs. The increasing number of generics is expected to result in the value erosion of the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Proteasome Inhibitors Market Customer Landscape
The proteasome inhibitors market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
Proteasome Inhibitors Market Scope |
|
Report Coverage |
Details |
Page number |
173 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.48% |
Market Growth 2024-2028 |
USD 2.91 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
6.6 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 43% |
Key countries |
US, Canada, UK, Germany, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Amgen Inc., Baxter International Inc., Bio Techne Corp., Bristol Myers Squibb Co., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson, Kezar Life Sciences Inc., LifeSensors Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., QLi5 Therapeutics, Takeda Pharmaceutical Co. Ltd., TG Therapeutics Inc., and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.